| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ELAVL1 |
| Uniprot No | Q15717 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-362aa |
| 氨基酸序列 | MSNGYEDHMAEDCRGDIGRTNLIVNYLPQNMTQDELRSLFSSIGEVESAK LIRDKVAGHSLGYGFVNYVTAKDAERAINTLNGLRLQSKTIKVSYARPSS EVIKDANLYISGLPRTMTQKDVEDMFSRFGRIINSRVLVDQTTGLSRGVA FIRFDKRSEAEEAITSFNGHKPPGSSEPITVKFAANPNQNKNVALLSQLY HSPARRFGGPVHHQAQRFRFSPMGVDHMSGLSGVNVPGNASSGWCIFIYN LGQDADEGILWQMFGPFGAVTNVKVIRDFNTNKCKGFGFVTMTNYEEAAM AIASLNGYRLGDKILQVSFKTNKSHK |
| 预测分子量 | 63 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于ELAVL1(HuR)重组蛋白的参考文献及其摘要概括：
1. **"HuR and mRNA stability"**
- **作者**: Brennan CM, Steitz JA
- **摘要**: 研究ELAVL1/HuR作为RNA结合蛋白在调控mRNA稳定性中的作用，利用重组HuR蛋白验证其与ARE(AU-rich element)序列的结合能力，揭示其在炎症和应激反应中的分子机制。
2. **"Post-translational modification of HuR regulates its interaction with cellular mRNAs"**
- **作者**: Doller A, et al.
- **摘要**: 通过重组HuR蛋白研究其磷酸化和泛素化修饰对mRNA结合的调控，发现修饰状态影响HuR在细胞质和核内的分布及靶标mRNA的稳定性。
3. **"HuR silencing inhibits cancer progression by suppressing oncogenic mRNAs"**
- **作者**: Mazan-Mamczarz K, et al.
- **摘要**: 利用重组ELAVL1蛋白进行体外RNA互作实验，证明HuR通过稳定促癌基因(如VEGF、Cyclin D1)的mRNA促进肿瘤进展，为靶向HuR的癌症治疗提供依据。
4. **"Expression and purification of functional recombinant HuR using a bacterial system"**
- **作者**: Lebedeva S, et al.
- **摘要**: 报道在大肠杆菌中高效表达和纯化功能性重组HuR蛋白的方法，并验证其RNA结合活性，为后续生化研究提供可靠工具。
以上文献涵盖ELAVL1重组蛋白的功能机制、修饰调控、疾病关联及制备方法，适用于分子生物学和疾病机制研究。
**Background of ELAVL1 Recombinant Protein**
ELAVL1 (Embryonic Lethal, Abnormal Vision, Drosophila-like 1), also known as HuR, is a ubiquitously expressed RNA-binding protein belonging to the ELAV/Hu family. It plays a critical role in post-transcriptional regulation of gene expression by binding to AU-rich elements (AREs) in the 3' untranslated regions (UTRs) of target mRNAs. This interaction stabilizes mRNAs, enhances their translation, or modulates splicing, thereby influencing cellular processes such as proliferation, apoptosis, inflammation, and stress responses. Dysregulation of ELAVL1 has been linked to cancers, neurodegenerative diseases, and autoimmune disorders, highlighting its therapeutic and diagnostic potential.
Recombinant ELAVL1 protein is engineered for experimental and biomedical applications. It is typically produced using bacterial (e.g., *E. coli*) or mammalian expression systems, followed by affinity purification to ensure high purity and activity. The recombinant protein retains functional RNA-binding domains, including three RNA recognition motifs (RRMs), enabling *in vitro* studies of RNA-protein interactions, mechanistic analyses, and drug screening. Researchers utilize it to investigate ELAVL1's role in mRNA stability, its interplay with signaling pathways (e.g., p38 MAPK), and its modulation by post-translational modifications (e.g., phosphorylation).
Additionally, recombinant ELAVL1 serves as a tool for developing inhibitors or stabilizers targeting its RNA-binding activity, which could lead to novel therapies for ELAVL1-associated diseases. Its application spans molecular biology, cancer research, and drug discovery, underscoring its importance in understanding post-transcriptional regulatory networks.
×
